

Date: 14.02.2020

To,

The Manager
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting under regulation 30 read Schedule III of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Ref:Sangam Health Care Products Limited (Scrip Code: 531625)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Sangam Health Care Products Limited held on Friday, the 14th day of February at 04.00 P.M. at the registered office of the Company the following were duly considered and approved by the Board:

1. Un-audited Financial Results for the quarter ended 31.12.2019
2. Limited Review Report for the quarter ended 31.12.2019.

The meeting concluded at 7.40 P.M.

This is for the information and records of the Exchange, please.

Thanking you,

Yours faithfully,

For Sangam Health Care Products Limited



A. Bala Gopal
Managing Director
(DIN: 01702903)



SANGAM HEALTH CARE PRODUCTS LIMITED
205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DEC 31, 2019

							(Rs.In Lakhs)
Particulars	Quarter ended			Nine Months ended		Year to Date figures for current period ended	
	31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Income from Operations							
(a) Net Sales/Income from Operations (Net of Excise duty)	609.10	666.87	515.30	1,784.73	1,620.46	2,103.92	
(b) Other Income-	-	0	-	315.31	-	4.03	
Total Income	609.10	666.87	515.30	2,100.04	1,620.46	2,107.95	
2 Expenditure							
(a) Cost of Raw material consumed	312.17	279.5	248.00	850.73	837.09	1,041.49	
(b) Purchase of stock-in-trade							
(c) Change in inventories of Finished Goods Works-in Progress and Stock in Trade	(23.06)	73.7	(73.28)	42.91	(73.38)	(125.85)	
(d). Employees Benefit Expenses	233.47	122.85	114.59	485.68	369.78	539.76	
(e). Depreciation and Amortization Expenses	42.53	34.11	37.98	114.21	114.12	150.26	
(f). Other Expenditure	81.62	162.51	202.58	370.69	551.46	763.12	
Total expenses	646.73	672.67	529.87	1,864.22	1,799.07	2,368.78	
3 Profit from Operations before Other Income, Financial Cost and Exceptional Items (1-2)	(37.63)	(5.80)	(14.57)	235.82	(178.61)	(260.83)	
4 Exceptional Items	-	-	-	-	-	(42.76)	
5 Profit / (Loss) from Ordinary Activities before tax (7+8)	(37.63)	(5.80)	(14.57)	235.82	(178.61)	(218.07)	
6 Current tax	-	-	-	-	-	-	
Deferred tax	-	-	-	-	-	(15.27)	
7 Net Profit (+)/Loss(-) from Ordinary Activities After Tax (9-10)	-37.63	-5.80	-14.57	235.82	-178.61	(202.80)	
8 Paid up equity share capital (no of shares) (face value of the share Rs.10/-)	1486.07	1486.07	1486.07	1486.07	1486.07	1,486.07	
9 Reserves excluding revaluation reserves	NIL	NIL	NIL	NIL	NIL	NIL	
10 Earning Per Share (EPS)	(0.0253)	(0.0039)	(0.0098)	0.1587	(0.1202)	(0.1365)	
a) Basic and diluted Eps before Extraordinary (not to be annualized)							
b) Basic and diluted Eps after Extraordinary (not to be annualized)							


Note :

- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at the meeting held on February,14, 2020
- The Limited Review of the Financials has been carried out by the Statutory Auditors of the Company in terms of of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.

Place : Secunderabad
Date: February 14, 2020

For Sangam Health Care Products Limited

Chairman and Managing Director





CA. M. RAMAKRISHNA
B.Com., F.C.A.
CHARTERED ACCOUNTANT

LIMITED REVIEW REPORT

To.
The Board of Directors.
Sangam Health Care Products limited

We have reviewed the accompanying statement of unaudited financial results of **Sangam Health Care Product Limited**, ("the company") Secunderabad for the quarter and nine months ended 31st Dec, 2019 ("the Statement"). Being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 Dated 5th July 2016.

This Statement is the responsibility of the Company's Management and approved by the board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410. "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express any audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards(AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Ramakrishna.
Chartered Accountant
Membership No.207169

Place: Hyderabad
Date: 14-02-2020

UDIN: **20207169AAAABG2203**

